首页> 外文期刊>BMC Public Health >Acceptability of lifelong treatment among HIV-positive pregnant and breastfeeding women (Option B+) in selected health facilities in Zimbabwe: a qualitative study
【24h】

Acceptability of lifelong treatment among HIV-positive pregnant and breastfeeding women (Option B+) in selected health facilities in Zimbabwe: a qualitative study

机译:定性研究:在津巴布韦选定的医疗机构中,HIV阳性孕妇和哺乳期妇女(选项B +)接受终生治疗的可接受性

获取原文
           

摘要

Background Zimbabwe’s Ministry of Health and Child Care (MOHCC) adopted 2013 World Health Organization (WHO) prevention of mother-to-child HIV transmission (PMTCT) guidelines recommending initiation of HIV-positive pregnant and breastfeeding women (PPBW) on lifelong antiretroviral treatment (ART) irrespective of clinical stage (Option B+). Option B+ was officially launched in Zimbabwe in November 2013; however the acceptability of life-long ART and its potential uptake among women was not known. Methods A qualitative study was conducted at selected sites in Harare (urban) and Zvimba (rural) to explore Option B+ acceptability; barriers, and facilitators to ART adherence and service uptake. In-depth interviews (IDIs), focus group discussions (FGDs) and key informant interviews (KIIs) were conducted with PPBW, healthcare providers, and community members. All interviews were audio-recorded, transcribed, and translated; data were coded and analyzed in MaxQDA v10. Results Forty-three IDIs, 22 FGDs, and five KIIs were conducted. The majority of women accepted lifelong ART. There was however, a fear of commitment to taking lifelong medication because they were afraid of defaulting, especially after cessation of breastfeeding. There was confusion around dosage; and fear of side effects, not having enough food to take drugs, and the lack of opportunities to ask questions in counseling. Participants reported the need for strengthening community sensitization for Option B+. Facilitators included receiving a simplified pill regimen; ability to continue breastfeeding beyond 6?months like HIV-negative women; and partner, community and health worker support. Barriers included distance of health facility, non-disclosure of HIV status, poor male partner support and knowing someone who had negative experience on ART. Conclusions This study found that Option B+ is generally accepted among PPBW as a means to strengthen their health and protect their babies. Consistent with previous literature, this study demonstrated the importance of male partner and community support in satisfactory adherence to ART and enhancing counseling techniques. Strengthening community sensitization and male knowledge is critical to encourage women to disclose their HIV status and ensure successful adherence to ART. Targeting and engaging partners of women will remain key determinants to women’s acceptance and adherence on ART under Option B+.
机译:背景津巴布韦卫生和儿童保育部(MOHCC)通过了2013年世界卫生组织(WHO)预防母婴HIV传播(PMTCT)的指南,建议开始对HIV阳性的孕妇和哺乳期妇女(PPBW)进行终身抗逆转录病毒治疗( ART),与临床阶段无关(选项B +)。选项B +于2013年11月在津巴布韦正式推出;然而,终生抗逆转录病毒疗法的可接受性及其在妇女中的潜在吸收率尚不清楚。方法在哈拉雷(城市)和兹维姆巴(农村)的选定地点进行了定性研究,以探讨方案B +的可接受性。障碍,并促进抗逆转录病毒疗法的依从性和服务吸收。与PPBW,医疗服务提供者和社区成员进行了深度访谈(IDI),焦点小组讨论(FGD)和关键信息提供者访谈(KII)。所有访谈均进行录音,转录和翻译;在MaxQDA v10中对数据进行编码和分析。结果进行了43个IDI,22个FGD和5个KII。大多数妇女接受终身抗逆转录病毒疗法。但是,由于他们害怕违约,特别是在停止母乳喂养之后,因此担心要终身服药。剂量方面有混淆;以及担心副作用,没有足够的食物来服药以及缺乏在咨询中提问的机会。与会者报告了需要加强社区对方案B +的认识。促进者包括接受简化的药物治疗方案;能够像HIV阴性妇女一样继续母乳喂养超过6个月;以及合作伙伴,社区和卫生工作者的支持。障碍包括医疗机构的距离,HIV状况的不公开,男性伴侣的支持不佳以及认识对ART经验不利的人。结论这项研究发现,PPBW中普遍接受Option B +作为加强其健康和保护其婴儿的一种手段。与先前的文献一致,本研究证明了男性伴侣和社区支持对令人满意地坚持抗逆转录病毒疗法和增强咨询技术的重要性。加强社区意识和男性知识对于鼓励妇女披露其艾滋病毒状况并确保成功遵守抗逆转录病毒疗法至关重要。确定和吸引女性合作伙伴仍然是决定女性在方案B +下接受和坚持接受抗逆转录病毒疗法的关键因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号